- Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
Key statistics
As of last trade, Lexaria Bioscience Corp (LEXX:NAQ) traded at 2.64, 274.41% above the 52 week low of 0.7051 set on Jul 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.66 |
---|---|
High | 2.72 |
Low | 2.61 |
Bid | 2.60 |
Offer | 2.66 |
Previous close | 2.64 |
Average volume | 115.15k |
---|---|
Shares outstanding | 14.32m |
Free float | 12.68m |
P/E (TTM) | -- |
Market cap | 37.81m USD |
EPS (TTM) | -0.6851 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 16:01 BST.
More ▼